Menu Search
Equities

Astellas Pharma Inc

4503N:MEX

Astellas Pharma Inc

Actions
  • Price (MXN)204.11
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Jan 12 2024 11:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Astellas Pharma Inc had net income fall -82.73% from 98.71bn to 17.05bn despite a 5.60% increase in revenues from 1.52tn to 1.60tn. An increase in the selling, general and administrative costs as a percentage of sales from 41.50% to 48.24% was a component in the falling net income despite rising revenues.
Gross margin81.78%
Net profit margin3.09%
Operating margin3.62%
Return on assets1.56%
Return on equity3.45%
Return on investment2.31%
More ▼

Cash flow in JPYView more

In 2024, cash reserves at Astellas Pharma Inc fell by 41.15bn. Cash Flow from Financing totalled 614.06bn or 38.29% of revenues. In addition the company generated 172.48bn in cash from operations while cash used for investing totalled 845.80bn.
Cash flow per share139.51
Price/Cash flow per share12.49
Book value per share854.61
Tangible book value per share-106.81
More ▼

Balance sheet in JPYView more

Astellas Pharma Inc has a Debt to Total Capital ratio of 37.74%, a higher figure than the previous year's 28.86%.
Current ratio1.10
Quick ratio0.8623
Total debt/total equity0.6063
Total debt/total capital0.3774
More ▼

Growth rates in JPY

SmartText is unavailable
Div yield(5 year avg)2.97%
Div growth rate (5 year)13.00%
Payout ratio (TTM)237.93%
EPS growth(5 years)-39.30
EPS (TTM) vs
TTM 1 year ago		44.79
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.